Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Nicholas Agresti

Gastroenterology Jacksonville, FL Medical Doctor

NPI 1669634010 CMS profile 1151107

1824 King St Ste 300, Jacksonville, FL 32204

Open in the dashboard

General payments

$9,874

533 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nicholas Agresti of Jacksonville, FL is reported in the CMS Open Payments database as having received $9,874 across 533 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Gastroenterology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,349 115
2024 General $2,444 119
2023 General $1,738 97
2022 General $1,743 106
2021 General $551 34
2020 General $299 16
2019 General $750 46

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nicholas Agresti
  • Gastroenterology median
  • Middle half of Gastroenterology
  • National median

In program year 2025, general payments to Nicholas Agresti were reported at $2,349. Among 13,050 Gastroenterology profiles paid that year, the median was $639 and the middle half received between $167 and $1,700.

Show as a table
Year Nicholas Agresti Gastroenterology median Middle half National median
2019 $750 $417 $126–$1,100 $163
2020 $299 $224 $74–$624 $114
2021 $551 $352 $106–$1,054 $132
2022 $1,743 $448 $129–$1,270 $149
2023 $1,738 $533 $150–$1,390 $160
2024 $2,444 $605 $160–$1,606 $164
2025 $2,349 $639 $167–$1,700 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $2,915 178 payments
  2. Madrigal Pharmaceuticals $904 44 payments
  3. Salix Pharmaceuticals, a division of Bausch Health US, LLC $792 48 payments
  4. Janssen Biotech, Inc. $647 39 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $588 32 payments
  6. Genzyme Corporation $556 25 payments
  7. Regeneron Healthcare Solutions, Inc. $490 22 payments
  8. QOL Medical, LLC $431 16 payments
  9. Celgene Corporation $378 27 payments
  10. Aimmune Therapeutics, Inc. $283 14 payments
  11. Other $1,889 88 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $9,874 533 payments
Products named General payments · program years 2019–2025
  1. RINVOQ $1,213 68 payments
  2. SKYRIZI $821 48 payments
  3. REZDIFFRA $744 34 payments
  4. LINZESS $673 43 payments
  5. CREON $651 40 payments
  6. XIFAXAN $625 38 payments
  7. HUMIRA $601 38 payments
  8. DUPIXENT Immunology $533 24 payments
  9. STELARA $510 30 payments
  10. DUPIXENT Inflammation And Immunology $387 17 payments
  11. Other $4,418 243 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 18 drugs

Part D claims

502

Median for Gastroenterology: 569

Drug cost

$992,231

Median for Gastroenterology: $104,976

Branded share of claims

36.9%

Median for Gastroenterology: 31.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Gattex Teduglutide Brand 12 $557,245
Humira(Cf) Pen Adalimumab Brand 13 $165,229
Creon Lipase/Protease/Amylase Brand 27 $124,114
Rezdiffra Resmetirom Brand 13 $85,890
Linzess Linaclotide Brand 20 $21,278
Movantik Naloxegol Oxalate Brand 11 $11,893
Budesonide Er Budesonide Brand 12 $11,184
Plenvu Peg3350/Sod Sul/Nacl/Kcl/Asb/C Brand 31 $4,428
Ursodiol Generic 28 $3,296
Omeprazole Generic 121 $3,073

The 10 drugs with the highest cost, of 18 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,294 Part D prescribers listed as Gastroenterology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 44 billing codes

Paid by Medicare

$101,725

Medicare's payments for the services billed

Medicare patients

451

Average age 74

Services billed

1,328

243 women, 208 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 50%
Ischemic heart disease 41%
Diabetes 40%
Chronic kidney disease 33%
Atrial fibrillation 29%
Heart failure 26%
Depression 25%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 22 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
$386 — —
RINVOQ
$351 — —
SKYRIZI
$214 — —
Sucraid
$186 — —
RESMETIROM
$161 13 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 22 in the dashboard with a free account

Records

533 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Gastroenterology in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record